These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 21135602)

  • 1. Vernakalant: a new drug to treat patients with acute onset atrial fibrillation.
    Tian D; Frishman WH
    Cardiol Rev; 2011; 19(1):41-4. PubMed ID: 21135602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vernakalant--a promising therapy for conversion of recent-onset atrial fibrillation.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Expert Opin Investig Drugs; 2008 May; 17(5):805-10. PubMed ID: 18447605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vernakalant in the management of atrial fibrillation.
    Cheng JW
    Ann Pharmacother; 2008 Apr; 42(4):533-42. PubMed ID: 18334607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous vernakalant: a review of its use in the management of recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs; 2011 Jan; 71(2):237-52. PubMed ID: 21275448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update.
    Tsuji Y; Dobrev D
    Vasc Health Risk Manag; 2013; 9():165-75. PubMed ID: 23637539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM; Roy D; Torp-Pedersen C; Wyse DG; Toft E; Juul-Moller S; Retyk E; Drenning DH;
    Am J Cardiol; 2010 Nov; 106(9):1277-83. PubMed ID: 21029824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vernakalant: RSD 1235, RSD-1235, RSD1235.
    Drugs R D; 2007; 8(4):259-65. PubMed ID: 17596113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE
    Curr Opin Investig Drugs; 2010 Sep; 11(9):1048-58. PubMed ID: 20730700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M
    Am J Health Syst Pharm; 2010 Jul; 67(14):1157-64. PubMed ID: 20592320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vernakalant: pharmacology electrophysiology, safety and efficacy.
    Naccarelli GV; Wolbrette DL; Samii S; Banchs JE; Penny-Peterson E; Stevenson R; Gonzalez MD
    Drugs Today (Barc); 2008 May; 44(5):325-9. PubMed ID: 18548135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of vernakalant in recent-onset atrial fibrillation after the European medicines agency approval: systematic review and meta-analysis.
    Buccelletti F; Iacomini P; Botta G; Marsiliani D; Carroccia A; Gentiloni Silveri N; Franceschi F
    J Clin Pharmacol; 2012 Dec; 52(12):1872-8. PubMed ID: 22167572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
    Cialdella P; Pedicino D; Santangeli P
    Recent Pat Cardiovasc Drug Discov; 2011 Jan; 6(1):1-8. PubMed ID: 21235460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E; Salghetti F; Bonadei I; Gelsomino S; Lorusso R; D'Aloia A; Curnis A
    Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of novel atrial-selective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): influence of CYP2D6 expression and other factors.
    Mao ZL; Wheeler JJ; Clohs L; Beatch GN; Keirns J
    J Clin Pharmacol; 2009 Jan; 49(1):17-29. PubMed ID: 18927241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of intravenous vernakalant for the rapid conversion of recent-onset atrial fibrillation: A meta-analysis.
    Akel T; Lafferty J
    Ann Noninvasive Electrocardiol; 2018 May; 23(3):e12508. PubMed ID: 29105209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vernakalant. Too dangerous in atrial fibrillation.
    Prescrire Int; 2012 May; 21(127):119-22. PubMed ID: 22827000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vernakalant hydrochloride to treat atrial fibrillation.
    Brown RA; Lau YC; Lip GY
    Expert Opin Pharmacother; 2014 Apr; 15(6):865-72. PubMed ID: 24617913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of vernakalant hydrochloride injection (RSD1235) in patients with atrial fibrillation or atrial flutter.
    Mao ZL; Townsend RW; Gao Y; Wheeler JJ; Kastrissios H; Keirns J
    J Clin Pharmacol; 2012 Jul; 52(7):1042-53. PubMed ID: 21659624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spotlight on intravenous vernakalant in recent-onset atrial fibrillation.
    Duggan ST; Scott LJ
    Drugs Aging; 2011 Jun; 28(6):501-4. PubMed ID: 21639409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C; Raev DH; Dickinson G; Butterfield NN; Mangal B; Beatch GN
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.